The COVID-19 pandemic put forth a revolutionary change in the pharma industry.
New, billion-dollar funding has revitalized research into once-overlooked health adversities and crafting new technologies to overcome them. Likewise, investment opportunities have emerged, setting the stage for an increasingly competitive market landscape. As geopolitical tensions continue to escalate and variants of COVID-19 emerge, pharma corporations are racing to learn what will define 2024 and beyond so as to become leaders within their sectors.
In this report, learn how recent US legislation, digital transformation, artificial intelligence (AI), the adoption of big data, and much more are redefining what medicine looks like for both patients and providers.
